DNA modifications by antitumor trans-[PtCl2(E-iminoether)2]

Molecular Pharmacology

Volumn 52, Issue 3, 1997, Pages 354-361

  Žaludová, Renata ^a   Žákovská, Alena ^a   Kašpárkova, Jana ^a   Balcarová, Zdenka ^a   Vrána, Oldřich ^a   Coluccia, Mauro ^b   Natile, Giovanni ^c   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b Sect Gen Pathol and Exp Oncol   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CISPLATIN DERIVATIVE; DIIMINOETHERDICHLOROPLATINUM II; DOUBLE STRANDED DNA; PLATINUM DERIVATIVE; TRANSPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA BINDING; DRUG DNA BINDING; DRUG EFFICACY; DRUG STRUCTURE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

EID: 1842294563     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.3.354     Document Type: Article

References (40)

1. Drobník, J. Antitumor activity of platinum complexes. Cancer Chemother. Pharmacol. 10:145-149 (1983).
2. Loehrer, P. J., and L. H. Einhorn. Cisplatin. Ann. Intern. Med. 100:704-713 (1984).
3. Clark, J. R., and A. I. Dreyfus. The role of cisplatin in treatment regimens for squamous cell carcinoma of the head and neck. Semin. Oncol. 18:34-38 (1991).
4. Raghavan, D., B. Pearson, W. H. Watt, H. Mameghan, P. Landgon, D. Eisinger, and R. Wines. Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimens. Semin. Oncol. 18:56-68 (1991).
5. Johnson, N. P., J.-L. Butour, G. Villani, F. L. Wimmer, M. Defais, V. Pierson, and V. Brabec. Metal antitumour compounds: the mechanism of action of platinum complexes. Prog. Clin. Biochem. Med. 10:1-24 (1989).
6. Lepre, C. A., and S. J. Lippard. Interactions of platinum antitumor compounds with DNA, in Nucleic Acids and Molecular Biology (F. Eckstein and D. M. J. Lilley, eds.). Springer-Verlag, Berlin/Heidelberg, 9-38 (1990).
7. Leng, M., and V. Brabec. DNA adducts of cisplatin, transplatin and platinum intercalating drugs, in DNA Adducts: Identification and Biological Significance (K. Hemminki, A. Dipple, D. E. G. Shuker, F. F. Kadlubar, D. Segerback, and H. Bartsch, eds.). International Agency for Research on Cancer, Lyon, IARC Scientific Publication no. 125, 339-348 (1994).
8. Farrell, N., L. R. Kelland, J. D. Roberts, and M. van Beusichem. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res. 52:5065-5072 (1992).
9. Coluccia, M., A. Nassii, F. Loseto, A. Boccarelli, M. A. Mariggio, D. Giordano, F. P. Intini, P. Caputo, and G. Natile. A trans-platinum complex showing higher antitumor activity than the cis congeners. J. Med. Chem. 36:510-512 (1993).
10. 3, pyridine). Biochemistry 32:9632-9638 (1993).
11. Kelland, L. R., C. F. J. Barnard, I. G. Evans, B. A. Murrer, B. R. C. Theobald, S. B. Wyer, P. M. Goddard, M. Jones, M. Valenti, A. Bryant, P. M. Rogers, and K. R. Harrap. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J. Med. Chem. 38:3016-3024 (1995).
12. Farrell, N. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry, in Metal Ions in Biological Systems (A. Sigel and H. Sigel, eds.). Marcel Dekker New York 603-639 (1996).
13. Goddard, P. M., R. M. Orr, M. R. Valenti, C. F. J. Barnard, B. A. Murrer, L. R. Kelland, and K. R. Harrap. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours. Anticancer Res. 16:33-38 (1996).
14. Coluccia, M., A. Boccarelli, M. A. Mariggio, N. Cardellicchio, P. Caputo, F. P. Intini, and G. Natile. Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Chem-Biol. Interact. 98:251-266 (1995).
15. 2]. Nucleic Acids Res. 24:336-341 (1996).
16. Eastman, A. The formation, isolation, and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 34: 155-166 (1987).
17. Cini, R., P. A. Caputo, F. P. Intini, and G. Natile. Mechanistic and stereochemical investigation of iminoethers formed by alcoholysis of coordinated nitrils: x-ray crystal structure of cis- and trans-[bis(1-imino-1-methoxyethane)dichloroplatinum(II)]. Inorg. Chem. 34:1130-1137 (1995).
18. Brabec, V., and E. Palec̀ek. The influence of salts and pH on polarographic currents produced by denatured DNA. Biophysik 6:290-300 (1970).
19. Kim, S. D., O. Vrána, V. Kleinwächter, K. Niki, and V. Brabec. Polarographic determination of subnanogram quantities of free platinum in reaction mixture with DNA. Anal. Lett. 23:1505-1518 (1990).
20. Lippard, S. J., H. M. Ushay, C. M. Merkel, and M. C. Poirier. Use of antibodies to probe the stereochemistry of antitumor platinum drug binding to deoxyribonucleic acid. Biochemistry 22:5165-5168 (1983).
21. Brabec, V., O. Vrána, V. I. Kiseleva, and A. M. Poverenny. Polyclonal antibodies elicited against trans-diamminedichloroplatinum(II)-modified DNA and their application in nonradioactive hybridization experiments. Eur. J. Biochem. 201:723-730 (1991).
22. Vrána, O., V. I. Kiseleva, A. M. Poverenny, and V. Brabec. Conversion of DNA adducts of antitumour cis-diamminedichloroplatinum(II). Immunochemical analysis. Eur. J. Pharmacol. 226:5-13 (1992).
23. Keck, M., and S. J. Lippard. Unwinding of supercoiled DNA by platinum-ethidium and related complexes. J. Am. Chem. Soc. 114:3386-3390 (1992).
24. Farrell, N., Y. Qu, L. Feng, and B. van Houten. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry 29: 9522-9531 (1990).
25. Lemaire, M.-A., A. Schwartz, A. R. Rahmouni, and M. Leng. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc. Natl. Acad. Sci. USA 88:1982-1985 (1991).
26. Brabec, V., and M. Leng. DNA interstrand cross-links of transdiamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc. Natl. Acad. Sci. USA 90: 5345-5349 (1993).
27. Konopa, J. Adriamycin and daunomycin induce interstrand DNA cross-links in HeLa S3 cells. Biochem. Biophys. Res. Commun. 110:819-826 (1983).
28. Culliname, C., A. van Rosmalen, and D. R. Phillips. Does adriamycin induce interstrand cross-links in DNA? Biochemistry 33:4632-4638 (1994).
29. Brabec, V., V. Boudný, and Z. Balcarová. Monofunctional adducts of platinum(II) produce in DNA a sequence-dependent local denaturation. Biochemistry 32:1316-1322 (1994).
30. Nováková, O., O. Vrána, V. I. Kiseleva, and V. Brabec. DNA interactions of antitumor platinum(IV) complexes. Eur. J. Biochem. 228:616-624 (1995).
31. Žaludová, R., V. Kleinwächter, and V. Brabec. The effect of ionic strength on melting of DNA modified by platinum(II) complexes. Biophys. Chem. 60:135-142 (1996).
32. Vrána, O., V. Brabec, and V. Kleinwächter. Polarographic studies on the conformation of some platinum complexes: relation to anti-tumour activity. Anticancer Drug Des. 1:95-109 (1986).
33. Brabec, V., J. Reedijk, and M. Leng. Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry 31: 12397-12402 (1992).
34. Paleček, E. Modern polarographic (voltammetric) techniques in biochemistry and molecular biology. Part II. Analysis of macromolecules, in Topics in Bioelectrochemistry and Bioenergetics (G. Milazzo, ed.). John Wiley & Sons, New York, 65-155 (1983).
35. Brabec, V., V. Kleinwächter, J.-L. Butour, and N. P. Johnson. Biophysical studies of the modification of DNA by antitumour platinum coordination complexes. Biophys. Chem. 35:129-141 (1990).
36. Paleček, E. Nucleic acid structure analysis by polarographic techniques, in Methods in Enzymology (L. Grossman and K. Moldave, eds.). Academic Press, New York/London, 3-24 (1971).
37. Bellon, S. F., J. H. Coleman, and S. J. Lippard. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 30:8026-8035 (1991).
38. Cohen, G. L., W. R. Bauer, J. K. Barton, and S. J. Lippard. Binding of cis and trans dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix. Science (Washington D. C.) 203:1014-1016 (1979).
39. Kane, S. A., and S. J. Lippard. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins. Biochemistry 35:2180-2188 (1996).
40. Pieper, R. O., S. L. Noftz, and L. C. Erickson. In vitro transcription termination by N,N′-bis(2-chloroethyl)-N-nitrosourea-induced DNA lesions. Mol. Pharmacol. 47:290-295 (1995).